<html>
 <body>
  <div class="col-md-12" id="content" style="">
   <div class="hidden" data-drupal-messages-fallback="">
   </div>
   <div class="widget block" id="block-medsites-page-title">
    <h1>
     <span property="schema:name">
      Myeloproliferative Neoplasms
     </span>
    </h1>
   </div>
   <div class="widget block" id="block-medsites-content">
    <article about="/commodorecompendium/myeloproliferative-neoplasms" data-history-node-id="2985" role="article" typeof="schema:WebPage">
     <div>
      <div class="field field--name-body field--type-text-with-summary field--label-hidden field__item" property="schema:text">
       <div class="WordSection1">
        <div style="border-bottom:solid windowtext 1.0pt; border-top:double windowtext 1.5pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Myeloproliferative Neoplasms (MPNs)—Christina Snider
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               <span style="color:black">
                Background
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 MPNs = chronic myeloid disorders caused by abnormal proliferation of mature bone marrow cell lineages (granulocytes, erythrocytes, or megakaryocytes)
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 MPNs differ from myelodysplastic syndrome (MDS)—cells in MPNs are normally developed (i.e. not dysplastic)
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Four “classic” MPNs: polycythemia vera, essential thrombocythemia, primary myelofibrosis and chronic myeloid leukemia (CML)
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; padding:0in">
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Polycythemia Vera (PV)
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Polycythemia is a general term: Men = Hb/Hct > 16.5/49%;  Women = Hb/Hct > 16/48%
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Relative polycythemia
                 </span>
                </span>
               </span>
              </b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 = Concentrated H/H due to
                 <i>
                 </i>
                 decreased plasma volume
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Diuretic use, vomiting, diarrhea;  H/H should normalize with fluid resuscitation
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Absolute polycythemia
                 </span>
                </span>
               </span>
              </b>
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 = Increased RBC mass
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
          <ul style="list-style-type:circle">
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Primary
                   </span>
                  </span>
                 </span>
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    polycythemia: 2/2 Inherited/acquired mutation in RBC progenitor
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </li>
           <li>
            <span style="page:WordSection1">
             <span style="font-size:11pt">
              <span style="line-height:normal">
               <span style="tab-stops:9.0pt">
                <span style="font-family:Calibri,sans-serif">
                 <span style="font-size:12.0pt">
                  <span style="font-family:Palatino">
                   <span style="color:black">
                    Secondary polycythemia: Increase in RBC mass due to elevated serum EPO
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
            <ul style="list-style-type:disc">
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="tab-stops:9.0pt">
                  <span style="font-family:Calibri,sans-serif">
                   <span style="font-size:12.0pt">
                    <span style="font-family:Palatino">
                     <span style="color:black">
                      Hypoxia/cardiopulmonary associated (chronic pulmonary disease, R-to-L cardiac shunts, sleep apnea, obesity hypoventilation syndrome, chronic carbon monoxide poisoning, including heavy smoking)
                     </span>
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="tab-stops:9.0pt">
                  <span style="font-family:Calibri,sans-serif">
                   <span style="font-size:12.0pt">
                    <span style="font-family:Palatino">
                     <span style="color:black">
                      Kidney associated causes (following renal transplant, renal artery stenosis, hydronephrosis)
                     </span>
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="tab-stops:9.0pt">
                  <span style="font-family:Calibri,sans-serif">
                   <span style="font-size:12.0pt">
                    <span style="font-family:Palatino">
                     <span style="color:black">
                      Autonomous EPO production from an EPO-producing tumors (rare)
                     </span>
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
             <li>
              <span style="page:WordSection1">
               <span style="font-size:11pt">
                <span style="line-height:normal">
                 <span style="tab-stops:9.0pt">
                  <span style="font-family:Calibri,sans-serif">
                   <span style="font-size:12.0pt">
                    <span style="font-family:Palatino">
                     <span style="color:black">
                      Steroid Use
                     </span>
                    </span>
                   </span>
                  </span>
                 </span>
                </span>
               </span>
              </span>
             </li>
            </ul>
           </li>
          </ul>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Epidemiology: Median age of diagnosis is 60 years; 25% cases present at age <50 years.
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 >95% PV pts have
                 <i>
                  JAK2
                 </i>
                 V617F mutation, but
                 <i>
                  JAK2
                 </i>
                 V617F mutation is not specific to PV and can be seen in other MPNs
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p style="margin-left:24px">
        </p>
        <p>
         <span style="page:WordSection1">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               <span style="color:black">
                Presentation
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Incidentally elevated H/H
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Splenomegaly, generalized pruritus (post-warm bath/shower), unusual thrombosis
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection1">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Erythromelalgia: intermittent occurrence of red, hot, painful extremities
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
       </div>
       <p>
       </p>
       <div class="WordSection2">
        <p>
         <span style="page:WordSection2">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               <span style="color:black">
                Evaluation
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 CBC with differential and peripheral smear
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 EPO level
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Rule out secondary causes: Sleep Study, Carboxyhemoglobin, steroids
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Peripheral blood screen for
                 <i>
                  JAK2
                 </i>
                 V617F mutation
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection2">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               <span style="color:black">
                Management
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 PV treatment aims to prevent thrombosis and bleeding events.
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Phlebotomy: maintain Hct <45% (One unit 500 mL decreases Hct by 3%)
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 ASA 81 mg for thrombosis prevention and symptom control
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Hydroxyurea: indicated for high-risk patients (>60 years old or with history of thrombosis)
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Interferon-alfa, busulfan, or ruxolitinib: indicated in select high-risk patients
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p style="margin-left:24px">
        </p>
        <div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
         <p style="border:none; margin-bottom:11px; padding:0in">
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <b>
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 Essential thrombocythemia (ET)
                </span>
               </span>
              </b>
             </span>
            </span>
           </span>
          </span>
         </p>
        </div>
        <p class="p1">
         <span style="page:WordSection2">
          <span style="font-size:6pt">
           <span style='font-family:"Helvetica Neue"'>
            <span style="color:#404040">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               <span style="color:black">
                Background
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Clonal stem cell disorder w/ increased platelet counts (>450k/uL)
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Risks of thrombosis and hemorrhage
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Median age of diagnosis: 60 years; Twice as common in females.
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p class="p1">
         <span style="page:WordSection2">
          <span style="font-size:6pt">
           <span style='font-family:"Helvetica Neue"'>
            <span style="color:#404040">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               <span style="color:black">
                Presentation
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Incidental thrombocytosis on CBC
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Splenomegaly, unusual thrombosis, and erythromelalgia
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p class="p1">
        </p>
        <p class="p1">
         <span style="page:WordSection2">
          <span style="font-size:6pt">
           <span style='font-family:"Helvetica Neue"'>
            <span style="color:#404040">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               <span style="color:black">
                Evaluation
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Screen for conditions that cause reactive thrombocytosis: Chronic inflammatory diseases, infections, bleeding/hemolysis, iron deficiency, post splenectomy
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 CBC with smear (platelet anisocytosis) ranging from very small to giant platelets
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 CMP, LDH, Uric Acid, iron studies
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 BCR ABL1 testing may be sent to exclude CML
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Bone marrow biopsy with staining, cytogenetics, and molecular testing for JAK2 mutations
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p>
        </p>
        <p>
         <span style="page:WordSection2">
          <span style="font-size:11pt">
           <span style="line-height:normal">
            <span style="font-family:Calibri,sans-serif">
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               <span style="color:black">
                Management
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </p>
        <ul>
         <li>
          <span style="page:WordSection2">
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="font-family:Calibri,sans-serif">
              <span style="font-size:12.0pt">
               <span style="font-family:Palatino">
                <span style="color:black">
                 Avoid ASA 81 in patients with platelet counts >1 million/uL microL complicated by acquired von Willebrand syndrome due to increased risk of bleeding
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </span>
         </li>
        </ul>
        <p style="margin-left:48px">
        </p>
        <table class="TableGrid3" style="border-collapse:collapse; border:none" width="348">
         <table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>0</th>
      <th>1</th>
      <th>2</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Treatment of ET</td>
      <td>Treatment of ET</td>
      <td>Treatment of ET</td>
    </tr>
    <tr>
      <td>Risk Score (IPSET-thrombosis)</td>
      <td>Features</td>
      <td>Treatment</td>
    </tr>
    <tr>
      <td>High</td>
      <td>Hx of thrombosis and/or &gt;age 60 with JAK2 V617F mutation</td>
      <td>Cytoreduction (target plt 100-400k) w/ hydroxyurea, systemic anticoagulation +/-antiplatelet agent</td>
    </tr>
    <tr>
      <td>Intermediate</td>
      <td>Age &gt;60, no JAK2 V617F mutation, no history of thrombosis</td>
      <td>Cytoreduction (target plt 100-400k) w/ hydroxyurea, systemic anticoagulation +/-antiplatelet agent</td>
    </tr>
    <tr>
      <td>Low</td>
      <td>Age =&lt;60 w/ JAK2 V617F mutation and no history of thrombosis</td>
      <td>Observation vs. daily ASA 81</td>
    </tr>
    <tr>
      <td>Very Low</td>
      <td>Age =&lt;60, no JAK2 V617F mutation, no history of thrombosis</td>
      <td>Observation vs. daily ASA 81</td>
    </tr>
  </tbody>
</table>
        </table>
        <p>
        </p>
       </div>
       <p>
       </p>
       <div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
        <p style="border:none; padding:0in">
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <b>
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Primary Myelofibrosis (PMF)
              </span>
             </span>
            </b>
           </span>
          </span>
         </span>
        </p>
       </div>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             <span style="color:black">
              Background
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Clonal proliferation of myeloid cells with variable morphologic maturity resulting in reactive marrow fibrosis and extramedullary hematopoiesis
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Least favorable prognosis out of MPN
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             <span style="color:black">
              Presentation
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Fatigue, weight loss, low grade fever, bone pain, and night sweats
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Marked splenomegaly +/-hepatomegaly (due to extramedullary hematopoiesis)
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             <span style="color:black">
              Evaluation
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               smear: teardrop shaped RBCs (dacrocytes)
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Bone marrow biopsy: “dry tap” due to extensive reticulin and/or collagen fibrosis
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               mutually exclusive mutations in
               <i>
               </i>
               JAK2, MPL, or CALR
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             <span style="color:black">
              Management
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Low risk patients: Observe if asymptomatic
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Cure by allogenic HCT transplantation in young, high risk patients
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Complex treatment options, consult Hematology
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Treatment of anemias include transfusion support
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Surgical splenectomy if abdominal pain or transfusion dependent anemia
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
       </p>
       <div style="border-bottom:solid windowtext 1.0pt; border-top:solid windowtext 1.0pt; border-left:none; border-right:none; padding:1.0pt 0in 1.0pt 0in">
        <p style="border:none; padding:0in">
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <b>
             <span style="font-size:12.0pt">
              <span style="font-family:Palatino">
               Chronic Myelogenous Leukemia (CML)
              </span>
             </span>
            </b>
           </span>
          </span>
         </span>
        </p>
       </div>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             <span style="color:black">
              Background
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Definition: MPN overproduction of myeloid stem cells that can differentiate
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Chronic phase: 85% of pts
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
         <ul style="list-style-type:circle">
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:9.0pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Fatigue, weight loss, bleeding
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:9.0pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  Abdominal fullness and early satiety due to splenomegaly
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
          <li>
           <span style="font-size:11pt">
            <span style="line-height:normal">
             <span style="tab-stops:9.0pt">
              <span style="font-family:Calibri,sans-serif">
               <span style="font-size:12.0pt">
                <span style="font-family:Palatino">
                 <span style="color:black">
                  WBC on CBC is typically >100k, and smear shows neutrophilic cells in all stages of maturation with <2% blasts
                 </span>
                </span>
               </span>
              </span>
             </span>
            </span>
           </span>
          </li>
         </ul>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Accelerated phase: Refractory leukocytosis, 10-19% blasts in peripheral blood or bone marrow, worsening peripheral basophilia, thrombocytopenia
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Blast phase = acute leukemia. >20% blasts in peripheral blood or bone marrow, extramedullary proliferation of blasts
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             <span style="color:black">
              Evaluation
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Typical findings in blood and bone marrow and confirmation of Philadelphia chromosome (
               <i>
                BCR-ABL1
               </i>
               fusion gene) via conventional cytogenetics, FISH, or rt-PCR
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
       <p>
       </p>
       <p>
        <span style="font-size:11pt">
         <span style="line-height:normal">
          <span style="font-family:Calibri,sans-serif">
           <span style="font-size:12.0pt">
            <span style="font-family:Palatino">
             <span style="color:black">
              Management
             </span>
            </span>
           </span>
          </span>
         </span>
        </span>
       </p>
       <ul>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Hydroxyurea can be used to reduce WBC while awaiting confirmation
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:11pt">
          <span style="line-height:normal">
           <span style="font-family:Calibri,sans-serif">
            <span style="font-size:12.0pt">
             <span style="font-family:Palatino">
              <span style="color:black">
               Oral tyrosine kinase inhibitors (TKIS): Imatinib, dasatinib, nilotinib, and ponatinib
              </span>
             </span>
            </span>
           </span>
          </span>
         </span>
        </li>
        <li>
         <span style="font-size:12.0pt">
          <span style="line-height:107%">
           <span style="font-family:Palatino">
            <span style="color:black">
             Allogenic hematopoietic cell transplantation: Curative option for pts in accelerated and blast phase, as well as young pts w/chronic phase CML who do not respond to TKI therapy
            </span>
           </span>
          </span>
         </span>
        </li>
       </ul>
      </div>
     </div>
    </article>
   </div>
  </div>
 </body>
</html>